Adicet Bio Inc Market Cap ($29.02 Million)
Market Cap & Net Worth: Adicet Bio Inc (ACET)
Adicet Bio Inc market cap. Adicet Bio Inc (NASDAQ:ACET) has a market capitalization of $29.02 Million ($29.02 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23703 globally and #5154 in its home market, demonstrating a -18.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adicet Bio Inc's stock price $3.10 by its total outstanding shares 9361490 (9.36 Million). Also see Adicet Bio Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Adicet Bio Inc Market Cap History (2018–2026)
Adicet Bio Inc market cap history from 2018 to 2026. Data shows change from $564.87 Million to $29.02 Million (-33.95% CAGR). Check ACET share price today for real-time trading data and today's change.
Index Memberships
Adicet Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #668 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #2215 of 3165 |
Weight: Adicet Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Adicet Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adicet Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Adicet Bio Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.35x
Adicet Bio Inc's market cap is 3.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $564.87 Million | $8.18 Million | -$9.30 Million | 69.05x | N/A |
| 2019 | $97.64 Million | $995.00K | -$28.14 Million | 98.13x | N/A |
| 2020 | $131.53 Million | $17.90 Million | -$36.68 Million | 7.35x | N/A |
| 2021 | $163.73 Million | $9.73 Million | -$62.00 Million | 16.83x | N/A |
| 2022 | $83.69 Million | $24.99 Million | -$69.79 Million | 3.35x | N/A |
Competitor Companies of ACET by Market Capitalization
Companies near Adicet Bio Inc in the global market cap rankings as of November 5, 2026. Also see Adicet Bio Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Adicet Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Adicet Bio Inc (2018–2026)
Market capitalization of Adicet Bio Inc from 2018 to today. Between 2018 and today, Adicet Bio Inc's market cap moved from $564.87 Million to $ 29.02 Million, with a yearly change of -33.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $29.02 Million | -63.18% |
| 2025 | $78.82 Million | +775.26% |
| 2024 | $9.01 Million | -49.10% |
| 2023 | $17.69 Million | -78.86% |
| 2022 | $83.69 Million | -48.89% |
| 2021 | $163.73 Million | +24.48% |
| 2020 | $131.53 Million | +34.71% |
| 2019 | $97.64 Million | -82.71% |
| 2018 | $564.87 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Adicet Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.02 Million USD |
| MoneyControl | $29.02 Million USD |
| MarketWatch | $29.02 Million USD |
| marketcap.company | $29.02 Million USD |
| Reuters | $29.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops … Read more